Drug Information

General Information
Drug ID
DR01489
Drug Name
Hydroxycamptothecin
Synonyms
10-Hydroxycamptothecin; 19685-09-7; (S)-10-Hydroxycamptothecin; Hydroxycamptothecin; 10-hydroxycamptothecine; 10-Hydroxy camptothecin; Hydroxycamptothecine; Camptothecin, hydroxy-; 10-Hydroxy-Camptothecin; (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; Camptothecin, 10-hydroxy-; Camptothecine, 10-hydroxy-; UNII-9Z01632KRV; NSC 107124; HCPT; (4S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-Hydroxycamptothecin hydrate; NSC107124
Drug Type
Small molecular drug
Indication Solid tumours [ICD11: 2D4Z] Phase 1 [1]
Structure
3D MOL 2D MOL
Formula
C20H16N2O5
Canonical SMILES
CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=CC(=CC5=C4)O)O
InChI
InChI=1S/C20H16N2O5/c1-2-20(26)14-7-16-17-11(5-10-6-12(23)3-4-15(10)21-17)8-22(16)18(24)13(14)9-27-19(20)25/h3-7,23,26H,2,8-9H2,1H3/t20-/m0/s1
InChIKey
HAWSQZCWOQZXHI-FQEVSTJZSA-N
CAS Number
CAS 19685-09-7
Pharmaceutical Properties Molecular Weight 364.4 Topological Polar Surface Area 100
Heavy Atom Count 27 Rotatable Bond Count 1
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 6
XLogP
0.6
PubChem CID
97226
PubChem SID
407052 , 645392 , 8140019 , 10228777 , 11342034 , 11362217 , 11364533 , 11367095 , 11369657 , 11372600 , 11375589 , 11377819 , 11404568 , 11485555 , 11487619 , 11489476 , 11491436 , 11493629 , 11495453 , 12015125 , 12173672 , 16124509 , 26612627 , 26680421 , 26750003 , 26758893 , 44427566 , 47348452 , 48392929 , 49831587 , 50028362 , 50107786 , 50122774 , 53787862 , 53790463 , 57336414 , 80013607 , 81093235 , 85788508 , 89360248 , 92721280 , 96024160 , 103071286 , 103082955 , 103170545 , 103922002 , 104420324 , 117586316 , 124636619 , 124891994
ChEBI ID
CHEBI:81395
TTD Drug ID
D07ILP
DT(s) Transporting This Drug MRP4 Transporter Info Multidrug resistance-associated protein 4 Substrate [2]
References
1 ClinicalTrials.gov (NCT01202370) A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies
2 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.